Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors.

Witkin JM, Rorick-Kehn LM, Benvenga MJ, Adams BL, Gleason SD, Knitowski KM, Li X, Chaney S, Falcone JF, Smith JW, Foss J, Lloyd K, Catlow JT, McKinzie DL, Svensson KA, Barth VN, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Pedregal C, Martínez-Grau MA, Post A, Ansonoff MA, Pintar JE, Statnick MA.

Pharmacol Res Perspect. 2016 Nov 7;4(6):e00275. doi: 10.1002/prp2.275. eCollection 2016 Dec.

2.

Emerging pharmacologic treatment options for fragile X syndrome.

Schaefer TL, Davenport MH, Erickson CA.

Appl Clin Genet. 2015 Apr 7;8:75-93. doi: 10.2147/TACG.S35673. eCollection 2015. Review.

3.

Therapeutic potential of metabotropic glutamate receptor modulators.

Hovelsø N, Sotty F, Montezinho LP, Pinheiro PS, Herrik KF, Mørk A.

Curr Neuropharmacol. 2012 Mar;10(1):12-48. doi: 10.2174/157015912799362805.

4.

Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study.

Kovačević T, Skelin I, Minuzzi L, Rosa-Neto P, Diksic M.

Brain Res Bull. 2012 Mar 10;87(4-5):406-12. doi: 10.1016/j.brainresbull.2012.01.010. Epub 2012 Jan 31.

5.

Allosteric modulation of metabotropic glutamate receptors.

Sheffler DJ, Gregory KJ, Rook JM, Conn PJ.

Adv Pharmacol. 2011;62:37-77. doi: 10.1016/B978-0-12-385952-5.00010-5. Review.

6.

The clinical implications of mouse models of enhanced anxiety.

Sartori SB, Landgraf R, Singewald N.

Future Neurol. 2011 Jul 1;6(4):531-571.

7.

The age of anxiety: role of animal models of anxiolytic action in drug discovery.

Cryan JF, Sweeney FF.

Br J Pharmacol. 2011 Oct;164(4):1129-61. doi: 10.1111/j.1476-5381.2011.01362.x. Review.

8.

Operant sensation seeking requires metabotropic glutamate receptor 5 (mGluR5).

Olsen CM, Childs DS, Stanwood GD, Winder DG.

PLoS One. 2010 Nov 30;5(11):e15085. doi: 10.1371/journal.pone.0015085.

9.

Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene variation with phenotypes relevant to autism spectrum disorders and Williams' syndrome.

Feyder M, Karlsson RM, Mathur P, Lyman M, Bock R, Momenan R, Munasinghe J, Scattoni ML, Ihne J, Camp M, Graybeal C, Strathdee D, Begg A, Alvarez VA, Kirsch P, Rietschel M, Cichon S, Walter H, Meyer-Lindenberg A, Grant SG, Holmes A.

Am J Psychiatry. 2010 Dec;167(12):1508-17. doi: 10.1176/appi.ajp.2010.10040484. Epub 2010 Oct 15.

10.

Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential.

Gregory KJ, Dong EN, Meiler J, Conn PJ.

Neuropharmacology. 2011 Jan;60(1):66-81. doi: 10.1016/j.neuropharm.2010.07.007. Epub 2010 Jul 14. Review.

11.

Allosteric modulators for mGlu receptors.

Gasparini F, Spooren W.

Curr Neuropharmacol. 2007 Sep;5(3):187-94. doi: 10.2174/157015907781695900.

12.

Prenatal restraint stress generates two distinct behavioral and neurochemical profiles in male and female rats.

Zuena AR, Mairesse J, Casolini P, Cinque C, Alemà GS, Morley-Fletcher S, Chiodi V, Spagnoli LG, Gradini R, Catalani A, Nicoletti F, Maccari S.

PLoS One. 2008 May 14;3(5):e2170. doi: 10.1371/journal.pone.0002170.

13.
14.

Transcriptional profiling of the rat frontal cortex following administration of the mGlu5 receptor antagonists MPEP and MTEP.

Gass JT, Olive MF.

Eur J Pharmacol. 2008 Apr 28;584(2-3):253-62. doi: 10.1016/j.ejphar.2008.02.032. Epub 2008 Feb 20.

15.

Role of functional magnetic resonance imaging in drug discovery.

Paulus MP, Stein MB.

Neuropsychol Rev. 2007 Jun;17(2):179-88. Epub 2007 Apr 10. Review.

Supplemental Content

Support Center